On March 25, 2025 iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, reported the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 25-30, 2025 in Chicago, Illinois (Press release, iTeos Therapeutics, MAR 25, 2025, View Source [SID1234651417]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details

Abstract 3136, "EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment and overcome resistance"

Session: Experimental and Molecular Therapeutics – Therapeutic Approaches to Attack the Tumor Microenvironment
Date and Time: Monday, April 28, 2025, 2:30 PM – 5:00 P.M. CDT
Location: Poster Section 24
Abstract 5609, "A novel PTPN1/2 inhibitor with high oral bioavailability enhances the antitumoral response"

Session: Experimental and Molecular Therapeutics – Kinase and Phosphatase Inhibitors 3
Date and Time: Tuesday, April 29, 2025, 2:30 PM – 5:00 P.M. CDT
Location: Poster Section 20
iTeos’ exhibit booth at the AACR (Free AACR Whitepaper) Annual Meeting is booth #3240.